Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Lance who wrote (9055)	11/6/1998 1:41:00 PM
From: Logistics	Read Replies (3) \| Respond to of 119973

CMGI puts. Yep, I agree. JL

To: Lance who wrote (9055)	11/6/1998 1:44:00 PM
From: NASDBULL	Read Replies (2) \| Respond to of 119973

What makes you all think that AVID filing will hit the business wires. A lot of things on Bloomberg never make it to the busines wires. These kinds of filings occur quite often in different companies. The significance is isolated to each companies situation. This is good news for AVID, but don't expect a media blitz like GERN(just joking). I love this day!!!!! NASDBULL P.S. Parked a huge position in LNDC, anyone with money to leave in a stock for a week or two, put it in LNDC.....safe bet and big things acomin!!

To: Lance who wrote (9055)	11/6/1998 1:51:00 PM
From: MoneyMade	Read Replies (1) \| Respond to of 119973

GERN!!!!!! HERE WE GO...MOVING MOVING$$ MONDAY HUGE GAPPER Geron Stock Up on Human Cell Report NEW YORK (AP) -- Geron Corp. (Nasdaq:GERN - news) shares more than doubled today after two research teams sponsored by the company disclosed advances in studies looking for ways to grow human tissue for transplants. Geron, a drug research company based in Menlo Park, Calif., holds the commercial rights to those human stem cells, which scientists also hope to use to introduce new genes into the body to remedy inherited disease. Geron was up $11.75 at $21.62 1/2 in Nasdaq trading at midday. Yesterday, the stock jumped 30 percent, as news of the breakthrough leaked to investors. Geron plans to sell cell types grown from stem cells to drug companies for use in laboratory drug testing. Geron also plans to research various transplant applications. Amid the euphoria, researchers admitted they haven't yet found an efficient way to develop stem cells into specific cell types, and it remained unclear how Geron will profit from the development in the short term. The two research teams were based at the University of Wisconsin and Johns Hopkins University in Baltimore. In a study published today in the journal Science, researchers at Wisconsin-Madison, announced they have cultured human stem cells, the foundation source of cells that during gestation form all body parts. Researchers at Johns Hopkins announced they also have isolated and grown stem cells. Their study is to be published later in the Proceedings of the National Academy of Sciences. Both teams said they have demonstrated the stem cell lines would transform into specific cell types, with specific functions, such as muscle, bone or nerve. Neither team was able to direct transformation, which occurred randomly. Thomas Okarma, research vice president of Geron, said his company hopes to use stem cells to regenerate failing tissues. ''Because these cells do not age, they could be used to generate virtually limitless supply of cells and tissue for transplantation,'' Okarma said. His firm helped to pay for some of the stem cell studies.